← Back to directory

Jan Walewski

Researcher Next ID · RN-013951

Researcher · Medicine

National Institute of Oncology

, Hungary

Not currently recruitingFunding unknown
Works count
459
Citation count
23,345
H-index
59
i10-index
171

Research interests

Medicine
Lymphoma Diagnosis and Treatment
Chronic Lymphocytic Leukemia Research
CNS Lymphoma Diagnosis and Treatment
CAR-T cell therapy research
Lung Cancer Treatments and Mutations

Publications

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology · 2015 · 10.1093/annonc/mdv304

  • Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

    The Lancet Oncology · 2011 · 10.1016/s1470-2045

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

    The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70235-2

  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

    European Journal of Cancer · 2010 · 10.1016/j.ejca.2010.10.013

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    The Lancet Oncology · 2006 · 10.1016/s1470-2045(06)70664-7

Current projects

    No projects listed.